Sabcomeline

Drug Profile

Sabcomeline

Alternative Names: BCI-224; CEB 242; Memric; SB-202026

Latest Information Update: 23 Jul 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer BrainCells; GlaxoSmithKline
  • Class Antidepressants; Imines; Quinuclidines; Small molecules
  • Mechanism of Action Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Cognition disorders; Major depressive disorder; Schizophrenia; Type 2 diabetes mellitus

Most Recent Events

  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
  • 26 Jun 2012 Sabcomeline is available for licensing as of 26 Jun 2012. http://www.braincellsinc.com
  • 19 Apr 2011 Phase-I clinical development in Cognition disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top